Randomized trialMedical2026

The Effects of Cannabinoids in Cardiovascular Disease: A Comprehensive Review.

Lopez A.; Haas M.; Mooradian A. · The American journal of medicine · 2026

Research summary

**Background & Methods** This is a narrative review synthesizing mechanistic, experimental, and epidemiologic evidence examining the relationships between cannabinoid exposure (THC and CBD) and cardiovascular disease outcomes. The review evaluates both acute and chronic cardiovascular effects, therapeutic potential of non-psychoactive cannabinoids, and identifies gaps in current research requiring future investigation. **Key Findings** - Cannabinoid type 1 (CB1) receptor activation in cardiovascular tissues promotes sympathetic nervous system activation, tachycardia, endothelial dysfunction, and vascular stiffness, while cannabinoid type 2 (CB2) receptor activation produces anti-inflammatory and atheroprotective effects - Acute THC exposure in humans produces tachycardia, increased myocardial oxygen demand, transient blood pressure alterations, and vascular stiffness - Recent large observational studies and meta-analyses demonstrate associations between cannabis/cannabinoid use and increased risk of major adverse cardiovascular events (MACE), though definitive causality remains unestablished; risks appear greatest with frequent and/or heavy use, particularly in individuals with pre-existing cardiovascular disease or multiple risk factors **Dosage & Administration** Not reported. The review does not specify particular cannabinoid doses or administration routes examined across studies. **Safety & Adverse Effects** Acute THC exposure produces tachycardia, increased myocardial oxygen demand, vascular stiffness, and blood pressure alterations. Chronic heavy use is associated with increased MACE risk. CB1 receptor-mediated sympathetic activation and endothelial dysfunction represent mechanistic pathways for cardiovascular harm. Vulnerable populations include individuals with underlying cardiovascular disease or multiple cardiovascular risk factors. **Evidence Quality** This narrative review synthesizes mixed evidence types (mechanistic, experimental, and epidemiologic) rather than conducting systematic meta-analysis. While observational studies and meta-analyses suggest cannabis-cardiovascular associations, the authors note causality has not been definitively established. Significant limitations include: lack of standardized cannabinoid exposure metrics across studies, reliance primarily on observational data with inherent confounding risk, absence of robust randomized controlled trials in human populations, and heterogeneity in study designs. The authors emphasize urgent need for standardized exposure assessment, longitudinal prospective studies, and RCTs to establish definitive causal relationships and risk quantification. Current evidence quality is moderate, supporting clinical screening for cannabinoid use but insufficient for definitive causality claims.

Summary generated by DeepWeed from the published abstract. See the original paper for full methods and results.

Journal
The American journal of medicine
Year
2026
Study type
Randomized trial
Read the original paper (DOI) ↗
Ask how this study fits the wider evidence — across 26,000+ papers.
Ask DeepWeed

More recent cannabis research

This page summarises published research for informational purposes only — it isn't medical advice. Always refer to the original publication for full methods, results and limitations.

← Back to home